PRESERVE-006: ONC-392 plus Pluvicto in ARTA resistant mCRPC

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
Principal Investigator
Headshot of Andrew John Armstrong
Professor of Medicine
Protocol Number
IRB: PRO00113824
NCT: NCT05682443
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL